Peter Allen Presenting at 2026 Pancreatic Cancer Consortium

Pancreatic Cancer Consortium Brings Researchers and Clinicians Together at Duke

Published

The Duke Cancer Institute Pancreatic Cancer Center hosted the 2026 Pancreatic Cancer Consortium, bringing together leading researchers and clinicians to discuss emerging research, new treatment approaches, and the future of pancreatic cancer care.

Led by Pancreatic Cancer Center Directors Peter Allen, MD, and Daniel Nussbaum, MD, the program highlighted advances taking place across the field. Vinod Balachandran, MD, discussed the potential of cancer vaccines in pancreatic cancer, while David Tuveson, MD, PhD, shared his perspective on the current state of pancreatic cancer research. Ignacio Garrido-Laguna, MD, PhD, presented on novel therapies for pancreatic ductal adenocarcinoma (PDAC).

The program also included a discussion on the future of RAS inhibitors, moderated by John Strickler, MD, as researchers considered their evolving role in pancreatic cancer treatment.

In addition to perspectives from leaders in the field, Pancreatic Cancer Center pilot grant recipients presented research underway at Duke, highlighting the innovative work being conducted across the institution.

The consortium provided an opportunity for researchers and clinicians to exchange ideas, explore new approaches, and strengthen collaborations focused on pancreatic cancer. These conversations support the Pancreatic Cancer Center’s broader mission to advance research and improve outcomes for patients with, or at risk for, pancreatic cancer. Thank you to everyone who participated.